Alteogen "ALT-B4-Based Keytruda SC Approved for Sale in Japan"
3 Articles
3 Articles
Alteogen announced on the 18th that Merck & MSD’s Keytruda SC, which incorporates ALT-B4—a core substance of the subcutaneous (SC) formulation change platform Hybrozyme®—has received manufacturing and sales approval in Japan. The Japanese product name is "Kiject." Keytruda SC is a product combining MSD’s immuno-oncology drug Keytruda (pembrolizumab) with Alteogen’s Verahyaluronidase Alpha.
(Seoul = Yonhap News) Reporter Shin Seon-mi = Alteogen [196170] announced on the 18th that MSD's Keytruda SC has received manufacturing and sales approval in Japan.
Alteogen [develops] MSD's Keytruda SC (Japanese product name .], which incorporates ALT-B4 (ingredient name verahyaluronidase alpha), a core substance of its subcutaneous (SC) formulation modification platform Hybrozyme.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
